Related Experiment Video
Updated: Feb 13, 2026

Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood
Published on: September 14, 2017
Generation of an anti-angiogenic endothelial progenitor cell line via endostatin gene transfer
Jing Ai1, Jun-Hui Sun2, Ting Wan1
1Eye Centre, The Second Affiliated Hospital of The School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China.
Abstract:
The viability of endothelial progenitor cells (EPCs) as a therapeutic treatment for neovascularization (NV) was subject to investigation in the present study. Furthermore, endostatin has previously been demonstrated to be an inhibitor of angiogenesis and a suppressant of vascular leakage. The aim of the present study was to generate transgenic EPCs with anti‑angiogenic effects for the treatment of ocular NV. EPCs were obtained from rat peripheral blood samples and then verified. A lentiviral‑endostatin‑green fluorescent protein recombinant construct was generated and used to infect EPCs. Transfected cells were then subjected to puromycin selection. Reverse transcription‑quantitative polymerase chain reaction and a western blot assay were then applied in order to determine both the endostatin mRNA and protein expression levels, respectively. In addition, vascular endothelial growth factor (VEGF) expression levels were also detected in order to observe the anti‑angiogenic effect of the endostatin‑transfected EPCs. Following puromycin (1 µg/ml) selection for 4 days, a stable endostatin‑transfected EPC line was generated. In this stable endostatin-transfected EPC line, the expression levels of endostatin increased; whereas the expression levels of VEGF decreased. The results of the present study revealed that EPCs can be genetically modified to overexpress endostatin, which may provide the cells with an anti‑angiogenic effect via increased expression of endostatin and decreased expression of VEGF. Thus, EPCs genetically modified to overexpress endostatin may serve as a potential therapeutic agent for ocular NV treatment.
Insights
Genetically engineered endothelial progenitor cells (EPCs) overexpressing endostatin show potential for treating ocular neovascularization (NV). This modification reduces vascular endothelial growth factor (VEGF) expression, offering an anti-angiogenic therapy.
Area of Science:
- Regenerative Medicine
- Molecular Biology
- Ophthalmology
Background:
- Endothelial progenitor cells (EPCs) are investigated for therapeutic neovascularization (NV).
- Endostatin inhibits angiogenesis and suppresses vascular leakage.
- Ocular NV requires novel anti-angiogenic therapies.
Purpose of the Study:
- To create transgenic EPCs with anti-angiogenic properties for ocular NV treatment.
- To genetically modify EPCs to overexpress endostatin.
- To evaluate the anti-angiogenic effect of endostatin-transfected EPCs.
Main Methods:
- EPCs isolated from rat peripheral blood.
- Lentiviral vector used for endostatin and green fluorescent protein gene transfer into EPCs.
- Reverse transcription-quantitative polymerase chain reaction and Western blot assays used to confirm gene and protein expression, including VEGF levels.
Main Results:
- Stable endostatin-transfected EPC line generated after puromycin selection.
- Increased endostatin mRNA and protein expression observed in transfected EPCs.
- Decreased vascular endothelial growth factor (VEGF) expression confirmed in endostatin-transfected EPCs.
Conclusions:
- EPCs can be successfully genetically modified to overexpress endostatin.
- Endostatin overexpression in EPCs confers an anti-angiogenic effect by modulating VEGF.
- Genetically modified EPCs represent a potential therapeutic strategy for ocular NV.
Related Concept Videos
Horizontal Gene Transfer
Cell Specific Gene Expression
Types of Genetic Transfer Between Organisms
Differentiation of Common Myeloid Progenitor Cells
Organization of Genes
Transfer RNA Synthesis
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...

